Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Merck & Co Inc V.MRK


Primary Symbol: MRK

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.


NYSE:MRK - Post by User

Post by rockport1on Aug 05, 2010 2:11am
293 Views
Post# 17323177

Distracted Management?

Distracted Management?Two of Merc's four directors, Plasden (CFO) and McBride, are also directors with Anaconda Mining (ANX). Anaconda is in the midst of commissioning their Pine Cove mill, and also in the middle of a hostile takeover battle for NIS (their partner at Pine Cove).  Given that McBride is actually the Chairman of the Board for ANX, I'm quite sure their focus at the moment is on Anaconda.
.
Perhaps they have devoted very little time to Merc over the past few months. This might explain why there has been minimal recognition of the impressive results and achievements of the Damoti Lake program this year. If management was focussed on this project, I'm sure we would have seen significant share appreciation as this story unfolded. It's time for management to do their job, get this story recognized, and support the share price. 
<< Previous
Bullboard Posts
Next >>